MUC1 and systemic sclerosis: The use of a placebo group of clinical trials, rather than prospective cohorts, is useful to evaluate the utility of short-term trends in KL-6 levels in predicting the subsequent progression of ILD in patients with SSc-ILD, although it totally depends on the availability of serum samples obtained repeatedly at short intervals.